- Leerink is out with a note on Dyax (DYAX +4.2%) which is interesting in light of recent developments on the ViroPharma (VPHM) takeout rumor front.
- Analyst Joseph Schwartz thinks "value is warranted for DX-2930," a fully human monoclonal antibody plasma kallikrein inhibitor for HAE expected to enter Phase 2 testing next year (the first patient in a Phase 1 trial was dosed last month). This is of course in addition to Kalbitor, the company's existing sub-Q plasma kallikrein inhibitor.
- Price target raised to $7 from $5.
- BioCryst (BCRX) is working on an oral option for HAE.
From other sites
at CNBC.com (Apr 3, 2014)
at CNBC.com (Jun 14, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs